Hemocompatibility and anti-fouling behavior of multilayer biopolymers immobilized on gold-thiolized drug-eluting cardiovascular stents.

To solve the thrombosis and restenosis problem in cardiovascular stent implantation for cardiovascular artery disease, chondroitin 6-sulfate (ChS) with heparin (HEP) have been used as drug carrier layers and alternatively covalently bonded on gold (Au)-dimercaptosuccinic acid (DMSA)-thiolized cardiovascular metallic (SUS316 L stainless steel, SS) stents. Sirolimus, a model drug, was encapsulated in the ChS-HEP alternative layers. The behavior of the drug in releasing and suppressing the growth of smooth-muscle cells (SMCs) was evaluated with 5-layer CHS-HEP coating on the SS stents. Moreover, hemocompatibility of blood clotting time and platelet adhesion was performed. The results showed that the 5-layer ChS-HEP-modified SS stents displayed the greatest hemocompatibility, showing prolonged blood clotting time of the activated partial thrombin time (> 500 s) and less platelet adhesion to reduce thrombosis. Furthermore, sirolimus can be released continuously for more than 40 days with the 5-layer ChS-HEP coating and is beneficial for inhibiting the growth of SMCs; however, it does not affect the proliferation of endothelial cells, which can avoid restenosis formation. Therefore, the multilayers of ChS-HEP grafted onto the Au-DMSA-cardiovascular SS stents provide high potential for use as drug eluting stents.